Europe Pharmaceutical Drug Delivery Market By Route of Administration [Oral (Tablet, Capsule), Injector, Topical (Cream, Transdermal Patch), Transmucosal, Nasal], Application [Cancer, Diabetes], Care Setting [Hospital, Homecare]-Forecast to 2031

icon1
USD 703.2
MARKET SIZE, 2031
icon2
CAGR 6.2%
(2026-2031)
icon3
460
REPORT PAGES
icon4
660
MARKET TABLES

OVERVIEW

europe-pharmaceutical-drug-delivery-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The Europe Pharmaceutical drug delivery market, valued at USD 519.6 million in 2026, is expected to expand to USD 703.2 million by 2031, reflecting a steady CAGR of 6.2% from 2025 to 2031. The Europe pharmaceutical drug delivery market is growing in response to a growing usage of biologics and biosimilars, a rising prevalence of chronic diseases, as well as an increasing acceptance of emerging drug delivery devices, including auto-injectors, prefilled syringes, and inhalation drug delivery devices. Furthermore, an aging population, growing usage of home care, and supportive regulatory policies that encourage patient-friendly drug delivery systems are also driving this market. The major trends in this market are self-administration, technology-driven drug delivery, sustainable drug delivery, and drug device combinations.

KEY TAKEAWAYS

  • By Country
    Germany is projected to witness the highest growth rate of 7.2% during the forecast period in the Europe pharmaceutical drug delivery market.
  • By Route of Administration
    By route of administration, the injectable drug delivery segment holds the largest share of 38.0% in 2025 in this market.
  • By Application
    By application, the autoimmune diseases segment is projected to experience the highest growth rate of 7.6% from 2026 to 2031.
  • By care setting
    By care setting, the hospital segment holds the largest share of 58.8% in 2025 in the Europe pharmaceutical drug delivery market.
  • Competitive Landscape - Major Players
    Gerresheimer AG (Germany) and Novo Nordisk (Denmark) stand out as star players in Europe because of their strong regional footprint, established product portfolios, and consistent leadership in advancing drug delivery technologies.
  • Competitive Landscape - Startups
    Capa Valve Ltd (Belgium) and Pharma Latch (UK) are emerging players, gaining attention for their novel approaches to improving precision, ease of use, and patient experience in drug delivery.

In the EU, a growing interest in innovative drug delivery systems has been seen, as healthcare systems search for ways to improve drug delivery. Countries such as Germany, France, and the Nordic countries are driving this forward with their healthcare budgets. Meanwhile, new development policies and increasing sustainability needs are encouraging innovations in device development to create patient-centered and sustainable drug delivery systems in the future.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

Some of emerging trends that are being noticed in Europe are the growing appeal of sustainable drug delivery packaging, using self-administration devices, and better integration of digital functionalities for compliance management. These emerging trends are influencing this market as companies are being compelled to innovate quickly, as a result of stricter government policies in the European Union.

europe-pharmaceutical-drug-delivery-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Rising prevalence of chronic diseases
  • Increasing adoption of connected and self-administration devices
RESTRAINTS
Impact
Level
  • Wide disparities in regulatory maturity and approval timelines
  • High-cost sensitivity in emerging markets
OPPORTUNITIES
Impact
Level
  • Growing demand for wearable injectors, and home-care delivery solutions
  • Government investments in digital health
CHALLENGES
Impact
Level
  • High competition from low-cost local players

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Rising prevalence of chronic diseases

The rising incidence of chronic diseases like diabetes, cardiovascular diseases, respiratory diseases, and cancer in Europe has led to a growing demand for enhanced drug delivery devices. The increasing number of new cases of chronic diseases in Western and Northern Europe, along with their rising adoption of biologics in clinical practices, has further propelled the necessity for injectable, respiratory, long-acting, and self-administration devices. These factors are thus fueling the development of this market in the European Union.

Restraint: Wide disparities in regulatory maturity and approval timelines

The relatively structured but very different regulatory ecosystem in Europe brings certain differences in timelines for drug delivery devices and combination products among various member nations of the European Union. Although certain geographic areas such as Germany, Nordic nations, and France are streamlined in their review processes, certain other nations from Southern and Eastern Europe take a longer time for device evaluation, and compliance for device-related standards in those regions remains in a developing stage.

Opportunity: Growing demand for wearable injectors, and home-care delivery solutions

This trend is being driven by a shift towards decentralized care, integration with digital health, and self-administration solutions as health systems across the region look to reduce hospital burdens. The growing utilization of biologics, combined with supportive reimbursement pathways across major EU markets, along with increasing investments in connected drug delivery platforms, further solidifies this growth path. Furthermore, the expansion of home care adoption among ageing populations, accompanied by the EU's activities concerning harmonised device regulations, creates additional layers of potential for effective market expansion across the diverse European healthcare systems.

Challenge: High competition from low-cost local players

There is intense competition from low-cost regional sources that are a challenge in the European pharmaceutical drug delivery market, especially in commoditized product lines such as syringes, infusion sets, and other delivery kit components. This market faces a potential import challenge from Turkey, as well as a low-cost alternative from manufacturers in the Central and Eastern European countries. The primary drawback of this low-cost alternative market competition model is that it compromises innovation in niche technologies, thereby generating a limited return on investment for established market leaders.

europe-pharmaceutical-drug-delivery-market: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
Builds a strong portfolio of injection-based delivery solutions, including smart pens, autoinjectors, and connected devices designed for diabetes, obesity management, and chronic care needs across Europe. These intuitive delivery systems simplify self-treatment, support accurate dosing, and help improve day-to-day therapy adherence, aligning well with Europe’s growing shift toward home-based care.
Offers a diverse set of delivery systems across oral, injectable, inhalation, and long-acting preparations, with particular emphasis on biologics, vaccines, and chronic therapeutic areas. This breadth provides flexibility across disease areas, supports rapid deployment of new therapies, and ensures reliable drug performance for Europe’s varied healthcare environments.
Specializes in precision-engineered primary packaging and drug delivery components, including prefillable syringes, inhalation parts, and device-integrated solutions tailored for European regulatory and manufacturing needs. High-performance components elevate dosing reliability, enhance safety standards, and enable seamless integration into pharma partners’ combination products, reinforcing Gerresheimer’s role as a key enabler for EU biologics and injectables.
Strengthens its delivery landscape through advanced inhalation technologies, subcutaneous biologic platforms, and targeted delivery systems for next-generation therapies. These innovations support more convenient treatment pathways, improve patient comfort, and demonstrate strong leadership in designing delivery systems suited for complex, evolving therapeutics.
Advances a wide mix of delivery formats—from oral and injectable options to lipid nanoparticle and mRNA-based systems—supported by deep formulation and controlled-release capabilities. This broad delivery toolbox allows Pfizer to support innovative biologics and vaccines while ensuring consistent, efficient drug administration for large patient populations across Europe.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The strong network of device manufacturers, global and regional pharma companies, and advanced healthcare institutions propels the adoption of innovative delivery systems, shaping the Europe pharmaceutical drug delivery ecosystem. This is supported by a well-defined regulatory framework led by EMA, MHRA, and national authorities to make sure that the standards for safety, combination-product evaluation, and market access are very high. All these put together create a mature, innovation-driven market with consistent demand for advanced injectable, inhalation, and transdermal delivery technologies.

europe-pharmaceutical-drug-delivery-market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

europe-pharmaceutical-drug-delivery-market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

By Application

The autoimmune diseases segment is one of the fastest-growing segments in applications within the EU during the period of 2026–2031, driven by the increasing cases of rheumatoid arthritis, psoriasis, and inflammatory bowel disease. With a greater pool of biologic and targeted therapies hitting the market-many with injectable or infusion-based mechanisms of delivery-demand for advanced systems also remains on the increase. Better diagnosis and wider access to treatments, along with a trend toward self-injectable options in therapies, add to the higher demand for specialized drug delivery solutions in the care of autoimmune diseases

By Care Setting

By care setting, hospitals are anticipated to register the largest share in 2025 due to their high volume of acute care, infusion, and complex biologics that require monitoring. Hospitals in Europe benefit from a superior purchasing position in their markets and a preference for adopting advanced infusion pumps, injectable, and controlled delivery systems early. Increasing surgical volumes, cancer cases, and emergency care also solidify that drug delivery remains, for now, in a hospital setting, despite the development of home healthcare options

By Route of Administration

Based on the route of administration, injectables are projected to lead in 2025 as a result of rising European reliance on biologics and biosimilars for cancer, autoimmune, and chronic diseases. These prefilled injectables in syringe, auto-injector, or pen form continue to be in vogue due to their ease of use, precision, and portability. Moreover, increasing acceptance of patient self-administration, coupled with support for combination product development, further validates injectables as the most popular administration routes in Europe

REGION

By Region

Germany is also likely to experience the fastest growth rate, with a well-functioning healthcare infrastructure, a high proportion of biologic prescriptions, and a rapid adoption rate of user-controlled devices such as auto-injectors and prefilled syringes. The country has a sizable number of seniors, an extensive hospital network, and favourable government policies that encourage the usage of superior delivery systems. In addition to that, Germany’s long-standing strength in R&D and manufacturing in the pharmaceutical domain keeps promoting injectable, inhalation, and wearable delivery systems for various therapy classes.

europe-pharmaceutical-drug-delivery-market Region

europe-pharmaceutical-drug-delivery-market: COMPANY EVALUATION MATRIX

The strong network of device manufacturers, global and regional pharma companies, and advanced healthcare institutions propels the adoption of innovative delivery systems, shaping the European pharmaceutical drug delivery ecosystem. This is supported by a well-defined regulatory framework led by EMA, MHRA, and national authorities to make sure that the standards for safety, combination-product evaluation, and market access are very high. All these put together create a mature, innovation-driven market with consistent demand for advanced injectable, inhalation, and transdermal delivery technologies.

europe-pharmaceutical-drug-delivery-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size in 2025 (Value) USD 501.6 MN
Market Size in 2031 (Value) USD 703.2 MN
CAGR 6.2%
Years Considered 2024–2031
Base Year 2025
Forecast Period 2026–2031
Units Considered Value (USD MN), Volume (Thousands Unit)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments Covered
  • By Route of administration:
    • Oral Drug Delivery
    • Injectable Drug Delivery
    • Topical Drug Delivery
    • Ocular Drug Delivery
    • Nasal Drug Delivery
    • Implantable Drug Delivery
    • Transmucosal Drug Delivery
  • By Application:
    • Infectious Diseases
    • Cancer
    • Cardiovascular Diseases
    • Diabetes
    • Respiratory Diseases
    • Central Nervous System Disorders
    • Autoimmune Diseases
    • Other Applications
  • By care setting:
    • Hospitals
    • Ambulatory Surgery Centers/ Clinics
    • Home Care Settings
    • Diagnostic Centers
    • Other Facilities of Use.
Regional Scope Germany, France, Italy, UK, Spain and Rest of Europe

WHAT IS IN IT FOR YOU: europe-pharmaceutical-drug-delivery-market REPORT CONTENT GUIDE

europe-pharmaceutical-drug-delivery-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Product Analysis Assessed key drug-delivery types in Europe—oral, injectable, inhalation, transdermal, implantable, nanoparticle-based, and connected devices. Evaluated performance, regulatory expectations, and innovation trends used by leading manufacturers. Helped clients select suitable delivery technologies, compare long-acting and device–drug options, and understand emerging platforms such as mRNA systems and smart injectors. Supported product planning for chronic disease and biologics-focused treatments.
Company Information Profiled major global and Europe drug-delivery players, covering portfolios, platforms, partnerships, manufacturing, and R&D efforts. Analyzed strengths in biologic and sustained-release delivery. Enabled clients to gauge competitor capabilities, assess supplier fit for injectables and device partners, and identify collaboration or outsourcing opportunities. Strengthened long-term strategy in biologics and advanced delivery solutions.
Geographic Analysis Examined Europe delivery trends across regulatory systems, biologics expansion, home-care adoption, and manufacturing hubs. Included reimbursement and digital-health ecosystem insights, with optional country-level customization. Supported strategic market entry by identifying growth areas, localization options, and supply-chain opportunities. Helped clients evaluate patient preferences and emerging demand in home-based and biologics-driven delivery segments across diverse Europe markets.

RECENT DEVELOPMENTS

  • May 2024 : Novartis took a step to expand its cancer care portfolio through the acquisition of Mariana Oncology which in turn gives the company access to next generation radioligand therapies for the most challenging oncology issues
  • July 2023 : GSK added to its respiratory pipeline via the purchase of Bellus Health which brought in camlipixant, a late stage P2X3 antagonist for refractory chronic cough
  • June 2023 : Merck expanded into the immunology and gastroenterology fields via the acquisition of Prometheus which brought to the company innovative products for the treatment of ulcerative colitis, Crohn’s disease and other auto immune issues
  • June 2023 : Merck expanded its immunology and gastroenterology pipeline via the acquisition of Prometheus which brought in to the company innovative candidates for ulcerative colitis, Crohn’s disease and other auto immune conditions

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
15
EXECUTIVE SUMMARY
20
PREMIUM INSIGHTS
25
MARKET OVERVIEW
30
INDUSTRY TRENDS
35
  • 5.1 PORTER’S FIVE FORCES ANALYSIS
  • 5.2 MACROECONOMICS OUTLOOK
    INTRODUCTION
    GDP TRENDS AND FORECAST
    TRENDS IN GLOBAL HEALTHCARE INDUSTRY
    TRENDS IN GLOBAL MEDICAL DEVICE INDUSTRY
  • 5.3 SUPPLY CHAIN ANALYSIS
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 ECOSYSTEM ANALYSIS
  • 5.6 PRICING ANALYSIS
    AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY CARE SETTING, 2025
    AVERAGE SELLING PRICE TREND, BY ROUTE OF ADMINISTRATION, 2023-2025
    AVERAGE SELLING PRICE TREND, BY COUNTRY, 2023-2025
    AVERAGE SELLING PRICE TREND, BY APPLICATION, 2023-2025
  • 5.7 TRADE ANALYSIS
    IMPORT SCENARIO (HS CODE 901831)
    EXPORT SCENARIO (HS CODE 901831)
  • 5.8 KEY CONFERENCES AND EVENTS, 2026–2027
  • 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
  • 5.10 INVESTMENT AND FUNDING SCENARIO
  • 5.11 CASE STUDY ANALYSIS/SUCCESS STORIES AND REAL-WORLD APPLICATIONS
  • 5.12 IMPACT OF 2025 US TARIFF ON EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET
    INTRODUCTION
    KEY TARIFF RATES
    PRICE IMPACT ANALYSIS
    IMPACT ON COUNTRY
    IMPACT ON END-USE INDUSTRIES
STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL, AND AI ADOPTIONS
50
  • 6.1 KEY EMERGING TECHNOLOGIES
    SMART & CONNECTED DRUG DELIVERY SYSTEMS
    NANOTECHNOLOGY-BASED DRUG DELIVERY
  • 6.2 COMPLEMENTARY TECHNOLOGIES
    3D-PRINTED AND PERSONALIZED DRUG DELIVERY SYSTEMS
    SMART CONNECTED INHALATION SYSTEMS
  • 6.3 ADJACENT TECHNOLOGIES
    SMART MONITORING, IOT & DATA-DRIVEN CONTROL
    NEXT-GENERATION FILTRATION & CONTAMINATION CONTROL
  • 6.4 TECHNOLOGY/PRODUCT ROADMAP
  • 6.5 PATENT ANALYSIS
  • 6.6 FUTURE APPLICATIONS
  • 6.7 IMPACT OF AI/GEN AI ON EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET
    TOP USE CASES AND MARKET POTENTIAL
    BEST PRACTICES IN EUROPE PHARMACEUTICAL DRUG DELIVERY
    CASE STUDIES OF AI IMPLEMENTATION IN EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET
    INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
    CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET
REIMBURSEMENT AND REGULATORY LANDSCAPE
70
  • 7.1 REGIONAL REGULATIONS AND COMPLIANCE
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    INDUSTRY STANDARDS
  • 7.2 REGIONAL REIMBURSEMENT ANALYSIS
  • 7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
  • 7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
90
  • 8.1 DECISION-MAKING PROCESS
  • 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
  • 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES IN EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET
  • 8.5 MARKET PROFITIBILITY
EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION & VOLUME, THOUSAND UNITS)
110
  • 9.1 INTRODUCTION
  • 9.2 INJECTABLE DRUG DELIVERY
    CONVENTIONAL INJECTION DEVICES
    - BY MATERIAL
    - BY RODUCT
    - BY USABILITY
    SELF-INJECTION DEVICES
    - NEEDLE-FREE INJECTORS
    - AUTOINJECTORS
    - PEN INJECTORS
    - WEARABLE INJECTORS
  • 9.3 ORAL DRUG DELIVERY
    SOLID ORAL DRUGS
    - TABLETS
    - CAPSULES
    - ORAL POWDERS
    - PILLS
    LIQUID ORAL DRUGS
    - ORAL SYRUPS
    - ORAL SOLUTIONS
    - ORAL EMULSIONS
    - ORAL ELIXIRS
    SEMI-SOLID ORAL DRUGS
    - ORAL GELS
    - ORAL PASTES
  • 9.4 TOPICAL DRUG DELIVERY
    LIQUID TOPICAL DRUG FORMULATIONS
    - TOPICAL SOLUTIONS
    - TOPICAL EMULSIONS
    - TOPICAL SUSPENSIONS
    SOLID TOPICAL DRUG FORMULATIONS
    - SUPPOSITORIES
    - POWDERS
    SEMI-SOLID TOPICAL DRUG FORMULATIONS
    - CREAMS
    - GELS
    - OINTMENTS
    - PASTES
    - LOTIONS
    TRANSDERMAL DRUG FORMULATIONS
    - TRANSDERMAL PATCHES
    - TRANSDERMAL GELS
    - TRANSDERMAL SPRAYS
  • 9.5 OCULAR DRUG DELIVERY
    LIQUID FORMULATIONS
    - EYE DROPS
    - LIQUID OCUALR SPRAYS
    SEMI-SOLID FORMULATIONS
    - OCUALR GELS
    - EYE OINTMENTS
    OCULAR DEVICES
    - DRUG COATED CONTACT LENSES
    - OCULAR INSERTS
  • 9.6 PULMONARY DRUG DELIVERY
    METHOD DOSE INHALERS
    DRY POWDER INHALERS
    NEBULIZERS
    - JET NEBULIZERS
    - ULTRASONIC NEBULIZERS
    - SOFT MIST NEBULIZERS
  • 9.7 NASAL DRUG DELIVERY
    NASAL DROPS
    NASAL SPRAYS
    NASAL POWDERS
    NASAL GELS
  • 9.8 TRANSMUCOSAL DRUG DELIVERY
    ORAL TRANSMUCOSAL FORMULATIONS
    - BUCCAL DRUG DELIVERY
    - SUBLINGUAL DRUG DELIVERY
    OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES
    - RECTAL TRANSMUCOSAL DRUG DELIVERY
    - VAGINAL TRANSMUCOSAL DRUG DELIVERY
  • 9.9 IMPLANTABLE DRUG DELIVERY
    ACTIVE IMPLANTABLE DRUG DELIVERY
    PASSIVE IMPLANTABLE DRUG DELIVERY
EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
130
  • 10.1 INTRODUCTTION
  • 10.2 INFECTIOUS DISEASES
  • 10.3 CANCER
  • 10.4 CARDIOVASCULAR DISEASES
  • 10.5 DIABETES
  • 10.6 RESPIRATORY DISEASES
  • 10.7 AUTOIMMUNE DISEASES
  • 10.8 CENTRAL NERVOUS SYSTEM DISORDERS
  • 10.9 OTHER APPLICATIONS
EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY CARE SETTING (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
150
  • 11.1 INTRODUCTION
  • 11.2 HOSPITALS
  • 11.3 AMBULATORY SURGICAL CENTERS/CLINICS
  • 11.4 HOME CARE SETTINGS
  • 11.5 DIAGNOSTIC CENTERS
  • 11.6 OTHER CARE SETTINGS
EUROPE PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRIES (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
170
  • 12.1 INTRODUCTION
  • 12.2 EUROPE
    GERMANY
    FRANCE
    ITALY
    UK
    SPAIN
    REST OF EUROPE
COMPETITIVE LANDSCAPE
190
  • 13.1 OVERVIEW
  • 13.2 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN
  • 13.3 REVENUE ANALYSIS, 2023-2025
  • 13.4 MARKET SHARE ANALYSIS, 2025
  • 13.5 BRAND/PRODUCT COMPARISON
  • 13.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2025
    - COMPANY FOOTPRINT
    - ROUTE OF ADMINISTRATION FOOTPRINT
    - APPLICATION FOOTPRINT
  • 13.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
    - DETAILED LIST OF KEY STARTUPS/SMES
    - COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • 13.8 COMPANY VALUATION & FINANCIAL MATRICS
  • 13.9 COMPETITIVE SITUATION AND TRENDS
    PRODUCT LAUNCHES
    DEALS
    EXPANSIONS
    OTHER DEVELOPMENTS
COMPANY PROFILES
210
  • 14.1 KEY PLAYERS
    JOHNSON & JOHNSON SERVICES, INC.
    PFIZER INC.
    FRESENIUS KABI
    BECTON, DICKINSON AND COMPANY
    NEMERA
    B. BRAUN
    GERRESHEIMER AG
    SHL MEDICAL
    NOVO NORDISK
    NOVARTIS
    SANOFI
    BAXTER INTERNATIONAL
    ASTRAZENECA
    ROCHE
    MEDMIX
  • 14.2 OTHER PLAYERS
    CAPA VALVE LTD.
    PHARMA LATCH
    ECO-INJECT
    ONDOSIS AB
    WINDGAP MEDICAL, INC.
RESEARCH METHODOLOGY
230
  • 15.1 RESEARCH DATA
    SECONDARY DATA
    - KEY DATA FROM SECONDARY SOURCES
    PRIMARY DATA
    - KEY DATA FROM PRIMARY SOURCES
    - KEY PRIMARY PARTICIPANTS
    - BREAKDOWN OF PRIMARY INTERVIEWS
    - KEY INDUSTRY INSIGHTS
  • 15.2 MARKET SIZE ESTIMATION
    BOTTOM-UP APPROACH
    TOP-DOWN APPROACH
    BASE NUMBER CALCULATION
  • 15.3 MARKET FORECAST APPROACH
    SUPPLY SIDE
    DEMAND SIDE
  • 15.4 DATA TRIANGULATION
  • 15.5 FACTOR ANALYSIS
  • 15.6 STUDY ASSUMPTIONS
  • 15.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT
APPENDIX
250
  • 16.1 INSIGHTS OF INDUSTRY EXPERTS
  • 16.2 DISCUSSION GUIDE
  • 16.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 16.4 CUSTOMIZATION OPTIONS
    GEOGRAPHIC ANALYSIS
    COUNTRY-LEVEL MARKET SHARE ANALYSIS
    COMPANY INFORMATION
    PRODUCT ANALYSIS
    COUNTRY-LEVEL VOLUME ANALYSIS
    ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST
    BY PRODUCT MARKET SHARE ANALYSIS (TOP 5 PLAYERS)
  • 16.5 RELATED REPORTS
  • 16.6 AUTHOR DETAILS

Methodology

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, fundamental market dynamics, and key player strategies.

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, SEC filings of companies and publications from government sources [such as National Institutes of Health (NIH), US FDA, US Census Bureau, World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), European Federation of Pharmaceutical Industries and Associations (EFPIA), American Journal of Drug Delivery and Therapeutics, Center for Drug Delivery and Nanomedicine (CDDN) and Parenteral Drug Association (PDA) were referred to identify and collect information for the global Europe Pharmaceutical Drug Delivery Market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the Europe Pharmaceutical Drug Delivery Market. The primary sources from the demand side include hospitals, ambulatory surgical centers/clinics, home care setting, diagnostic centers among others. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.

Market Estimation Methodology

For the global market value, annual revenues were calculated based on the revenue mapping of major product manufacturers and OEMs active in the global Europe Pharmaceutical Drug Delivery Market. All the major product manufacturers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/sub-segments was done for the major players (who contribute at least 45-48% of the market share at the global level). Also, the global Europe Pharmaceutical Drug Delivery Market was split into various segments and sub-segments based on:

  • List of major players operating in the pharmaceutical drug delivery  products market at the regional and/or country level
  • Product mapping of various pharmaceutical drug delivery  manufacturers at the regional and/or country level
  • Mapping of annual revenue generated by listed major players from pharmaceutical drug delivery (or the nearest reported business unit/product category)
  • Revenue mapping of major players to cover at least 45% of the global market share as of 2023
  • Extrapolation of the revenue mapping of the listed major players to derive the global market value of the respective segments/subsegments
  • Summation of the market value of all segments/subsegments to arrive at the global point-of-care  diagnostics market

The above-mentioned data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.

Data Triangulation

After arriving at the overall size of the global Europe Pharmaceutical Drug Delivery Market through the above-mentioned methodology, this market was split into several segments and subsegments. The data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact market value data for the key segments and subsegments. The extrapolated market data was triangulated by studying various macro indicators and regional trends from both demand- and supply-side participants.

Market Definition

Drug delivery is a method or process of administration of a pharmaceutical drug to safely attain its desired therapeutic effect. Advancements in drug delivery offer several benefits, such as ease of use, convenience, and patient compliance. Drug delivery technologies are used for the targeted delivery and/or controlled release of therapeutic agents.

Key Market Stakeholders

  • Pharmaceutical manufacturing companies
  • Original equipment manufacturing companies
  • Suppliers and distributors of pharmaceutical products and medical devices
  • Healthcare service providers
  • Teaching hospitals and academic medical centers
  • Health insurance players
  • Government bodies/municipal corporations
  • Regulatory bodies
  • Medical research institutes
  • Business research and consulting service providers
  • Venture capitalists
  • Market research and consulting firms

Report Objectives

  • To define, describe, and forecast the global Europe Pharmaceutical Drug Delivery Market on the basis of pharmaceutical drug delivery  product, route of administration, application, facility of use, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the overall market
  • To analyze the opportunities in the market for key stakeholders and provide details of the competitive landscape for major market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America (the US and Canada), Europe (Germany, the UK, France, Italy, Spain, and Rest of Europe), Asia Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East & Africa
  • To profile the key market players and comprehensively analyze their market shares and core competencies2
  • To track and analyze competitive developments such as mergers and acquisitions, new product developments, partnerships, agreements, collaborations, and expansions in the global Europe Pharmaceutical Drug Delivery Market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the global Europe Pharmaceutical Drug Delivery Market report.

Product Analysis

  • Product Matrix, which gives a detailed comparison of the product portfolios of the top five global players.

Company Information

  • Detailed analysis and profiling of additional market players (up to 5 players)

Geographic Analysis

  • Further breakdown of the Rest of Europe Europe Pharmaceutical Drug Delivery Market into Belgium, Austria, the Netherlands, Switzerland, Austria, Finland, Sweden, Poland, and Portugal, among other
  • Further breakdown of the Rest of Asia Pacific Europe Pharmaceutical Drug Delivery Market into New Zealand, Vietnam, Philippines, Singapore, Malaysia, Thailand, and Indonesia, among other countries
  •  Further breakdown of the Rest of Latin America Europe Pharmaceutical Drug Delivery Market into Argentina, and Colombia, among other countries.

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Europe Pharmaceutical Drug Delivery Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Europe Pharmaceutical Drug Delivery Market

DMCA.com Protection Status